 |
|
|
Arthritis research
Research article
Perforin deficiency attenuates collagen-induced
arthritis
Kristin Bauer
, Annika Knipper
, Hoang Tu-Rapp
, Dirk Koczan
, Hans-Jurgen Kreutzer
, Horst Nizze
, Eilhard Mix
, Hans-Juergen Thiesen
, Rikard Holmdahl
and Saleh M Ibrahim
Institute of Immunology, University of Rostock,
Rostock, Germany
Institute of Pathology, University of Rostock,
Rostock, Germany
Institute of Neurology, University of Rostock, Rostock, Germany
Section for Medical Inflammation Research, Lund University, Lund,
Sweden
author email
corresponding author email
Arthritis Research &
Therapy 2005, 7:R877-R884doi:10.1186/ar1758
The electronic version of this article is the
complete one and can be found online at: http://arthritis-research.com/content/7/4/R877
| Received: |
24 September 2004 |
| Revisions requested: |
14 October 2004 |
| Revisions received: |
22 March 2005 |
| Accepted: |
15 April 2005 |
| Published: |
20 May 2005 |
Abstract
Collagen-induced arthritis (CIA), an approved animal model for
rheumatoid arthritis, is thought to be a T cell-dependent disease.
There is evidence that CD8+ T cells are a major subset controlling
the pathogenesis of CIA. They probably contribute to certain features
of disease, namely tissue destruction and synovial hyperplasia.
In this study we examined the role of perforin (pfp), a key molecule
of the cytotoxic death pathway that is expressed mainly in CD8+
T cells, for the pathogenesis of CIA. We generated DBA/1J mice
suffering from mutations of the pfp molecule, DBA/1J-pfp-/-, and
studied their susceptibility to arthritis. As a result, pfp-deficient
mice showed a reduced incidence (DBA/1J-pfp+/+, 64%; DBA/1J-pfp-/-,
54%), a slightly delayed onset (onset of disease: DBA/1J-pfp+/+,
53 ± 3.6; DBA/1J-pfp-/-, 59 ± 4.9 (mean ± SEM), and milder form
of the disease (maximum disease score: DBA/1J-pfp+/+, 7.3 ± 1.1;
DBA/1J-pfp-/-, 3.4 ± 1.4 (mean ± SEM); P < 0.05). Concomitantly,
peripheral T cell proliferation in response to the specific antigen
bovine collagen II was increased in pfp-/- mice compared with
pfp+/+ mice, arguing for an impaired killing of autoreactive T
cells caused by pfp deficiency. Thus, pfp-mediated cytotoxicity
is involved in the initiation of tissue damage in arthritis, but
pfp-independent cytotoxic death pathways might also contribute
to CIA .
Introduction
Collagen-induced arthritis (CIA) is an experimental model of
arthritis inducible in susceptible strains of mice, for example
DBA1/J, by immunization with bovine collagen type II (CII) in
complete Freund's adjuvant (CFA) [1-4]. The development of CIA
is known to depend on T cells, and disease susceptibility is linked
to the major histocompatibility complex (MHC) region [5]. After
T cell activation an inflammatory cascade involving T cells, macrophages/monocytes,
B cells, and activated synoviocytes, is triggered. Different types
of leucocytes and synovial cells produce a complex array of cytokines
and other soluble mediators, which are thought to be responsible
for cartilage destruction and bone erosion [6-9]. Some
of the main features of disease are synovial hyperplasia and
mononuclear cell infiltration. Factors contributing to this phenomenon
are unknown; however, an imbalance between rates of cell proliferation
and cell death (apoptosis) has been suggested by recent studies
of rheumatoid synovium demonstrating that apoptosis of synovial
cells and infiltrating lymphocytes was common in situ [10,11].
In the immune system, apoptosis is involved in development and
in the negative selection of lymphocytes. It is also crucial in
downregulating immune responses to foreign antigens. Cytotoxic
T lymphocytes and other killer cells can eliminate their targets
by the induction of cell death. All of these functions are primarily
mediated through the receptors Fas/APO-1, tumor necrosis factor
receptor 1 (TNFR1; p55 TNFR) and the perforin (pfp)/granzyme pathway
[12,13].
Perforin is expressed mainly in activated cytotoxic T lymphocytes
(CTLs) and natural killer (NK) cells, although some reports suggest
its expression in microglia as well [14]. In CTLs, pfp is stored
in cytoplasmic granules and is a major effector of cytolysis by
these cells. On pfp release it inserts itself into the plasma
membrane of target cells and polymerizes into pore forming aggregates.
Pores of pfp lead to osmotic lysis of target cells and induce
apoptosis by allowing granzymes to enter the target cells. Perforin-deficient
mice have confirmed its function as an effector molecule and in
the immune response to viruses and tumors as well as in other
aspects of immune regulation such as activation-induced cell death
(AICD), antibody production and spontaneous autoimmunity [15-17].
NOD mice, an animal model of insulin-dependent diabetes mellitus
with a mutation of the pfp gene (NOD/pfp-mice), develop diabetes
with highly reduced incidence and markedly delayed onset, pointing
to a role of the pfp death pathway in tissue damage in this disease
[18].
The role of pfp in arthritis is not clear, although some observations
suggest a role in disease pathogenesis, for example pfp-expressing
CTLs has been demonstrated in the rheumatoid synovium, and CD8-deficient
mice seem to be less susceptible to induction of collagen-induced
arthritis [19].
It is conceivable that the pfp/granzyme pathway could contribute
to the pathology of arthritis in at least two ways: promotion
of autoimmunity by blocking peripheral tolerance and AICD or destruction
of target tissues. In this study we attempted to evaluate the
role of the pfp-mediated death pathway in the pathogenesis of
CIA with the use of pfp-deficient mice (pfp-/-) by examining the
effect of the mutation on the clinical course of disease, immune
response to collagen and on joint pathology.
Materials and methods
Mice
Perforin-deficient mice were not available on the DBA/1J background.
We obtained pfp-/- C57BL/6J (B6) mice, generated as described
previously [15], from the Jackson Laboratories (Bar Harbor, ME,
USA). These mice were backcrossed onto the CIA-susceptible DBA/1J
background (Harlan-Winkelmann, Borchen, Germany) for at least
14 generations. The mice were propagated as hemizygous mutants
and the mutations were followed by PCR analysis of tail DNA. To
produce homozygous pfp-/- mice for the experiments, heterozygous
pfp-deficient mice were intercrossed. Successful backcrossing
to the DBA/1J background was assessed by PCR analysis of the MHC-H2
locus [20]. To select mice heterozygous for the pfp-deficiency
the primers 5'-TTT TTG AGA CCC TGT AGA CCC A-3' (pfp1) and 5'-GCA
TCG CCT TCT ATC GCC TTC T-3' (pfp2) were used. For selection of
homozygous pfp-deficient mice, pfp3 primer (5'-CCG GTC CTG AAC
TCC TGG CCA A-3') was used in combination with pfp4 primer (5'-CCC
CTG CAC ACA TTA CTG GAA G-3'). Microsatellite markers (Metabion
GmbH, Planegg-Martinsried, Germany) surrounding the pfp gene were
used for determining the size of the C57BL/6J DNA fragment in
the mutant mice. The amplified microsatellites were separated
and analyzed on denaturing polyacrylamide gels, and were detected
with a LI-COR Model 4200L automated DNA sequencer (LI-COR Inc.,
Lincoln, NE, USA). For the experiments male mice 8 to 16 weeks
old were used. Animals were kept and bred under standard conditions
at the facility of the University of Rostock. All experiments
were approved by the appropriate authorities in the state of Mecklenburg-Vorpommern,
Germany.
Induction and clinical evaluation of collagen-induced
arthritis
Age-matched mice were immunized intradermally at the base of the
tail with 125 μg of bovine CII (Chondrex, Redmond, WA, USA) emulsified
in CFA (incomplete Freund's adjuvant containing 4 mg/ml Mycobacterium
tuberculosis; Difco Laboratories, Detroit, IL, USA) or with CFA
only. Mice were then boosted with 125 μg of bovine CII in incomplete
Freund's adjuvant at day 21. Blood were taken at day 0 and day
21 before boosting, and serum was collected. Clinical scores were
assessed immediately before immunization (day 0) and thereafter
three times weekly. Inflammation of the four paws was scored as
follows: 0, no inflammation; 1, swelling or redness of one joint;
2, swelling or redness of more than one joint or mild inflammation
of the whole paw; 3, severe inflammation of whole paw or ankylosis.
CFA-immunized mice served as controls.
T cell proliferation response
Popliteal, preperioteneal, inguinal, mesenterial, axillary and
cervical lymph nodes were removed under aseptic conditions. Single-cell
suspensions of mononuclear cells of pooled lymph nodes from individual
mice were prepared. The cells were cultured in triplicates in
flat-bottomed 96-well culture plates, at a concentration of 2
x 106 cells in 200 μl of medium (RPMI 1640 with Glutamax-II supplemented
with 50 IU/ml penicillin, 60 μg/ml streptomycin (Gibco, Karlsruhe,
Germany) and 5% heat-inactivated fetal calf serum). To investigate
the antigen-specific response, lymphocytes were stimulated with
10, 1 or 0.1 μg/ml bovine CII; 4 μg/ml concanavalin A (Difco)
was used as positive control, and medium only was used as negative
control. Cells were incubated for 72 hours at 37°C in a humidified
atmosphere containing 5% CO2. To measure the proliferation by
DNA synthesis, cells were pulsed with 1 μCi of [3H]thymidine for
the last 12 hours of culture. Cells were harvested onto glass
fiber filters, and [3H]thymidine incorporation was measured in
a liquid β-scintillation counter. The results were expressed as
counts per minute.
Cytokine ELISA
To analyze cytokine production, cells were cultured as described
above; supernatant was collected after 72 hours in vitro antigen
challenge. Concentrations of IFN-γ in the supernatants were determined
by the Cytoscreen Immunoassay Kit (BioSource, Camarillo, CA, USA)
in accordance with the instructions of the manufacturer. In brief,
the lymphocyte supernatant was added to an ELISA-plate coated
with a monoclonal antibody specific for mouse IFN-γ. After incubation
and washing, a biotinylated polyclonal antibody specific for mouse
IFN-γ was added. Then streptavidin-peroxidase and later the substrate
solution were added to detect the products of the reaction.
Anti-CII antibody assay
The serum from the mice was analyzed with ELISA for the quantification
of IgG antibodies against CII. Micro-ELISA plates were coated
overnight at 4°C with 50 μl of PBS containing 5 μg/ml bovine CII
in each well. After washing, the sera were added and incubated
at 37°C for 2 hours. After 1 hour of incubation at 37°C with anti-mouse-IgG
conjugated with alkaline phosphatase (Pharmingen BD), p-nitrophenylphosphate
containing substrate buffer (Sigma) was added, and 3 M NaOH was
used to stop the reaction. The plates were read at 405 nm.
Histopathology
Mice were killed and paws were cut off and subsequently fixed
in 4% paraformaldehyde solution. After decalcification for 2 to
3 weeks in an EDTA solution the paws were embedded in paraffin.
The paws were sectioned and stained with H & E. Evaluation
of disease was made according to a previously published scale
[21]: 1, synovial hyperplasia; 2, start of pannus development;
3, erosions of bone and cartilage; 4, severe inflammation and
erosions.
Fluorescence-activated cell sorting analysis
For the determination of T cell, B cell and NK cell populations
in the different pfp-mice, lymphocytes were isolated and stained
with fluorescein isothiocyanate (FITC)-labeled anti-CD4 antibody
(Pharmingen; clone H129.19), phycoerythrin-labeled anti-CD8a antibody
(Pharmingen; clone 43-6.7), FITC-labeled anti-CD45R/B220 antibody
(Pharmingen; clone RA3-6B2), phycoerythrin-labeled anti-CD90 antibody
(Pharmingen; clone OX-7), and anti-IgG-biotin and streptavidin-FITC
before being analyzed by FACScan (Becton Dickinson; with Cell
Quest software version 1.2.2).
Statistics
Statistical evaluation was performed with SPSS software. For analyzing
differences in clinical scores, a Mann-Whitney test was used.
For incidence calculations, X2 and Fisher tests were used. When
analyzing differences in cytokine production and T cell proliferation,
Student's unpaired t-test was used. Differences were considered
significant at P < 0.05.
Results
Characterization of the pfp-deficient DBA/1J mice
The pfp-deficient mice were originally derived from C57BL/6J strain
by embryonic stem cell transfer. Because this strain is resistant
to CIA induction, we backcrossed the mice for at least 14 generations
into the CIA-susceptible DBA/1J background. The pfp gene is located
on chromosome 10 at 36 cM, and the mutant gene was inherited as
a C57BL/6J fragment of about 10 cM between about 28 and 39 cM
(Table 1). To exclude the possibility that backcrossing with the
DBA/1J strain revealed a defect in T cell, B cell or NK cell maturation
we examined distribution of these different immune cell populations
by fluorescence-activated cell sorting. It was found that T lymphocytes
expressing CD4 and CD8, as well as CD90+ cells (CD90 is expressed
on T cells and NK cells) and CD45R/B220-positive cells (B cells,
activated killer cells) were present at comparable percentages
in heterozygous and pfp-deficient DBA/1J mice, indicating that
the lack of pfp did not affect development of these cell populations
in the DBA/1J strain (data not shown). The lack of pfp expression
in the activated T cells of the pfp-/- mice was confirmed at the
RNA level by RT-PCR (see 1).
Pfp-deficient mice are less susceptible to collagen-induced
arthritis
To investigate the role of pfp in collagen-induced arthritis,
we immunized DBA-pfp-/-, DBA-pfp+/- and DBA-pfp+/+ mice with bovine
CII in CFA. As shown in Fig. 1 and Table 2, mice deficient for
pfp developed a less severe disease with lower clinical scores
than mice with intact pfp. DBA-pfp-/- mice also showed a tendency
to a delayed onset of CIA. Mice with intact pfp (pfp+/+ and pfp+/-)
had an average incidence of 64%, whereas pfp-/- mice showed a
mean incidence of 54% (Fig. 1). The severity of disease was decreased
on day 50 after immunization (pfp-/-, 0.9 ± 0.86; pfp+/-, 1.4
± 0.67; pfp+/+, 1.3 ± 0.47 (means ± SEM)), and on day 75 (pfp-/-,
2.1 ± 1.7; pfp+/-, 3.8 ± 1; pfp+/+, 5.2 ± 1.2), and significantly
decreased on day 82 (pfp-/-, 3.0 ± 1.5; pfp+/-, 4.0 ± 0.9; pfp+/+,
5.6 ± 0.9; P < 0.05). Maxscore, calculated as the mean of the
maximum score value for each individual mouse of a given genotype,
was also significantly decreased in pfp-deficient mice (pfp-/-
3.4 ± 1.45) in comparison with pfp+/+ mice (7.3 ± 1.14; Fig. 1).
In addition, the area under the curve, as a measure of severity,
onset and chronicity, was significantly lower in pfp-/- mice than
in mice carrying pfp (pfp-/-, 31.9 ± 23; pfp+/-, 44.6 ± 12.3).
 |
Histopathological features of CIA do not change with
pfp deficiency
To investigate joint histopathology, paws were dissected from
pfp-/- and pfp+/- mice with CIA, H & E-stained and evaluated
blind for signs of arthritis. Results (Fig. 2) reveal that pfp-/-
mice can develop a severe arthritis with typical signs of CIA,
namely proliferation of synoviocytes, infiltration of inflammatory
cells, pannus development, and erosions of bone and cartilage.
Comparing both genotypes, no differences in histopathological
development of the disease were visible (Fig. 2).
 |
Lack of pfp does not affect the antibody response to
collagen To investigate the role of pfp on the humoral
immune response to collagen, sera were obtained from pfp-/-, pfp+/-
and pfp+/+ mice at days 0 and 21 after immunization, and the levels
of CII-specific IgG antibodies were measured by quantitative ELISA.
No significant variations were seen in the levels of anti-CII-specific
IgG between the pfp-/- and pfp+/- or pfp+/+ littermates (Fig.
3). Pfp-deficient mice showed a mean titer of anti-CII antibodies
of 233 ± 51.1, and the control group had a mean titer of anti-CII
antibodies of 306 ± 50.8 at day 21 after immunization. These data
show that even without pfp the mice develop a strong humoral immune
response against CII, suggesting that the lack of pfp does not
affect the anti-CII antibody response.
 |
Pfp-/- mice mount an enhanced proliferative T cell response
toward CII
To investigate whether the T cell response against CII was affected
by pfp deficiency, draining the lymph nodes of immunized pfp-/-
and pfp+/+ was investigated for the proliferative response toward
bovine CII. Perforin-deficient mice showed an enhanced T cell
proliferation compared with pfp wild-type mice. As shown in Fig.
3, after stimulation with 0.1 μg/ml CII, pfp-/- mice showed a
significantly elevated T cell proliferation of 12,835 ± 2,750
cpm compared with 4,727 ± 1,268 cpm in pfp+/+ mice; at a CII concentration
of 1 μg/ml the T cell proliferation was also significantly increased
in pfp-deficient mice (32,209 ± 6,764 cpm) compared with pfp-wild-type
mice (21,904 ± 2,626 cpm). The IFN-γ production of T cells from
these mice was measured by ELISA, but no significant differences
between pfp-/- and pfp+/+ mice were observed (data not shown).
Discussion
The primary aim of this study was to investigate whether the
delayed onset and mild arthritis observed earlier in CD8-/- mice
[19] is due to a lack of cytotoxic ability or a lack of some other
aspects of T cell function such as the secretion of cytokines.
Indeed, we found that pfp-deficient mice develop disease with
reduced incidence, a slightly delayed onset, and significantly
decreased severity, suggesting that CTL activity is important
for the initiation and maintenance of arthritis in the CIA model.
This is in agreement with earlier observations in the insulin-dependent
diabetes mellitus (NOD) mouse model. In that model, as in CIA,
pfp is a susceptible rather than a protective gene. This is in
contrast to other disease models, for example experimental autoimmune
encephalomyelitis (EAE), systemic lupus erythematosus (SLE) and
autoimmune pancreatitis, in which pfp clearly protects against
the disease [16-18,22]. The protective effects of pfp could be
explained by its immune regulatory function, namely the killing
of autoreactive B cells and functional self-lysis of activated
T cells through AICD. Hence, its role in regulation of peripheral
tolerance and its role in autoimmunity, which is distinct from,
but overlaps, the role of the FasL/Fas and TNF/TNFR pathways,
might be the reason for accelerated autoimmunity in pfp-deficient
mice in the EAE and SLE models.
In the present study we obtained evidence that pfp can also act
as a susceptibility gene rather than a protective gene. A lack
of the molecule led to reduced severity throughout the disease,
a slightly delayed onset, and a reduced incidence of CIA. However,
we also observed a strong anti-collagen B cell response with similar
anti-collagen-specific IgG levels in control and pfp-/- mice,
and significantly increased T cell proliferation in response to
collagen. This might have been due to a reduced killing and accumulation
of autoreactive T cells after activation because of impaired AICD.
These findings indicate that a diminished adaptive response to
collagen was not responsible for the reduced arthritis.
Previous studies demonstrated a strong involvement of pfp in
the control of CD8+ T cell homeostasis. Perforin deficiency resulted
in enhanced CD8+ T cell expansion because of decreased killing
of antigen-presenting cells and consequential prolonged stimulation
by antigen [23,24]. Our results support these propositions: we
observed a significantly increased T cell proliferation in pfp-deficient
mice in comparison with controls. These data also suggest a role
of pfp in the regulation of T cell homeostasis. Nevertheless,
cytokines produced by cytotoxic T cells are also involved in the
regulation of the T cell response. TNF-α, for example, can mediate
AICD of CD8+ T cells through TNFR1 and TNFR2 [25].
The histopathology of CIA in wild-type pfp+/+ mice of the present
study was similar to that seen in previous studies [26]. The data
are therefore not shown again here. In the present study there
were no significant differences between histopathological changes
of pfp+/- and pfp-/- mice, most probably because of a severe disease
in individual pfp-/- mice. This result argues for an additional
involvement of pfp-independent death pathways in joint destruction.
Indeed, pfp was upregulated in the inflamed arthritic joints of
wild-type mice as shown by RT-PCR (1).
This is similar to our recent finding showing that the FasL/Fas
pathway has a proinflammatory role in CIA and an activating function
on fibroblasts in vitro [27]. Fas-deficient mice developed arthritis
that was less severe, probably through a reduced IL-1R1/Toll-like
receptor-4 signaling that might contribute to a decreased expression
of other cytokines, chemokines and matrix metalloproteinases potentially
regulated by this pathway [28]. Previous studies also reported
a strong involvement of the TNF/TNFR pathway because CIA only
developed with a reduced disease incidence, and the severity and
neutralization of TNF led to the prevention of arthritis [29,30].
Taken together, the results show that in CIA the disease-promoting
effect of pfp prevails. It is therefore tempting to speculate
that pfp could contribute to arthritis in at least two ways. First,
it could promote tissue damage by direct cytotoxic effects through
CD8+ T cells and NK cells. Second, pfp might have some activating
functions on fibroblasts or macrophages, leading to the production
of proinflammatory cytokines. Indeed, there are reports indicating
that fibroblasts and monocytes can be activated by granzyme A
to secrete the proinflammatory cytokines IL-6, IL-8 and TNF-α,
which could subsequently severely regulate the inflammatory response
[31,32].
There are other indications that argue for a prominent role of
pfp in arthritis. Perforin was found to be differentially expressed
in lymph nodes and joints of DBA/1J and FVB/N (CIA-resistant strain)
mice (SM Ibrahim and D Koczan, unpublished observations) and pfp-expressing
cytotoxic T lymphocytes and increased apoptosis were observed
in the synovia of patients with rheumatoid arthritis [10,33,34].
The targeted pfp gene is likely to have a major role in the observed
effects, on the basis of the absence of pfp production, although
it is possible that other polymorphic genes in the linked region
could also contribute to CIA reduction. Indeed, the pfp gene is
mapped to a CIA-susceptible locus, Cia8 on chromosome 10. This
quantitative trait locus is covered by the 12 cM C57BL/6J fragment
including the mutant pfp gene. The Cia8 region contains several
candidate genes that have been implicated in the modulation of
CIA susceptibility, for example the macrophage migration inhibitory
factor Mif [35] and the autoimmune regulator Aire [36]. However,
the observation that heterozygous littermates and pfp+/+ mice
that were also backcrossed and contained the same or smaller C57BL/6J
fragments do not show effects on the disease argues against a
major role for another gene.
In summary, the CIA in pfp-deficient mice was mild and showed
delayed onset and reduced incidence, but some individual pfp-/-
mice also developed a severe disease. These results suggest that
pfp-dependent cytotoxicity is involved in the initiation of tissue
damage in arthritis, but that pfp-independent cytotoxic death
pathways, for example the FasL/Fas pathway, might also contribute
to CIA.
Conclusion
We report that arthritis developed only with reduced incidence,
severity and delayed onset in pfp-deficient DBA/1J mice. These
findings suggest that pfp-dependent cytotoxicity is involved in
the initiation of tissue damage in arthritis but also that one
or several other pfp-independent mechanisms, possibly involving
FasL/Fas, contribute to the early phase of joint destruction in
CIA.
Abbreviations
AICD = activation-induced cell death; CFA = complete Freund's
adjuvant; CIA = collagen-induced arthritis; CII = collagen type
II; CTL = cytotoxic T lymphocyte; EAE = experimental autoimmune
encephalomyelitis; ELISA = enzyme-linked immunosorbent assay;
FITC = fluorescein isothiocyanate; H & E = hematoxylin and
eosin; IFN = interferon; IL = interleukin; MHC = major histocompatibility
complex; NK = natural killer; RT-PCR = reverse transcriptase polymerase
chain reaction; pfp = perforin; SLE = systemic lupus erythematosus;
TNF = tumor necrosis factor.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
KB, AK and HTR did the experimental work and contributed to writing
the manuscript. KB and AK contributed equally to the work. DK,
HJT, RH and SMI participated in the design and co-ordination of
the study and drafted the manuscript. HJK and HN did the histopathology.
EM carried out the T cell proliferation and cytokine assays. All
authors read and approved the final manuscript.
Acknowledgements
We thank I Klamfuss, E Lorbeer and R Waterstradt for excellent technical
assistance. This work was supported by grants from the DFG (DFG
243/1) and EU (EUROME) QL.
|
 |